How Proteostasis Will Capitalize on Its Big Cystic Fibrosis Win
Proteostasis Therapeutics shares pulled back on Tuesday after the company announced that it would be conducting a secondary offering.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 118
Why Mirati Therapeutics Is Sinking
Mirati shares dropped on Monday after the company announced updated positive clinical data from its midstage study in non-small cell lung cancer.
Entasis Therapeutics Called to Have Huge Upside from Analysts, But Poor IPO Performance Clouds Sentiment
Analysts very bullish on Entasis Therapeutics ETTX
Axonics Announces Potential Pricing for IPO
Medical technology company Axonics Modulation Technologies is offering more than 6 million shares in an initial public offering valued up to more than $122 million.
Top Biotech Earnings Reports to Watch This Week
Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming week.
Jefferies Out With 5 Biotech Stocks Under $10 With Gigantic Upside Potential
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
Why Clovis Oncology Faces Some Difficulty With Its Midstage Cancer Study
Clovis Oncology shares dropped on Friday after the company announced initial data from its Phase 2 clinical trial of Rubraca at the ESMO 2018 Congress.
Why Merrimack Pharma Is Terminating Its Midstage Lung Cancer Study
Merrimack Pharmaceuticals shares dropped early on Friday after the company announced that it would be terminating its midstage SHERLOC study in patients with non-small cell lung cancer.
LogicBio Therapeutics Announces Potential Pricing for IPO
Genome editing company LogicBio Therapeutics expects to price more than 5 million shares for an initial public offering valued up to almost $93 million.
Why Proteostasis Shares Are Skyrocketing
Proteostasis Therapeutics shares absolutely exploded on Thursday after the company announced positive preliminary results from its early-stage cystic fibrosis trial.
Are Endocyte Investors Getting Enough in the Buyout?
Endocyte shares were up sharply early Thursday after it was announced that the company would be acquired.
Twist Bio Announces Potential Pricing for IPO
Synthetic biology company Twist Bioscience expects to price 5 million shares for an initial public offering valued up to more than $103 million.
Merck’s Pancreatic Cancer Treatment Gets FDA Nod
Merck shares were up handily on Tuesday after the company announced a key update from the FDA on its Lynparza for the treatment of pancreatic cancer.
UnitedHealth Earnings Show Why It Is a Top Dow Stock
UnitedHealth released better-than-expected third-quarter financial results before the markets opened on Tuesday.
Should Johnson & Johnson Be Getting More Out of Q3 Earnings?
Johnson & Johnson reported better-than-expected third-quarter financial results before the markets opened on Thursday.